Harbin Gloria Pharmaceuticals Co. Ltd. A | Ownership
Companies that own Harbin Gloria Pharmaceuticals Co. Ltd. A
Yunnan International Trust Co., Ltd.
49,305,626
2.27%
49,305,626
1.12%
09/30/2017
Shaanxi International Trust Co. Ltd. (Invt Mgmt)
24,010,534
1.11%
24,010,534
0.69%
09/30/2017
China Investment Corp. (Investment Management)
15,767,700
0.73%
0
0.03%
09/30/2017
China Asset Management Co., Ltd.
4,233,587
0.2%
-15,738,211
0.01%
12/31/2017
China Southern Asset Management Co., Ltd.
4,003,236
0.19%
-129,200
0.02%
12/31/2017
Guotai Junan Allianz Fund Management Co., Ltd.
2,190,895
0.1%
-344,700
0.09%
12/31/2017
The Vanguard Group, Inc.
2,133,075
0.1%
0
0%
07/31/2018
GF Fund Management Co., Ltd.
929,011
0.04%
100
0.01%
12/31/2017
SWS MU Fund Management Co., Ltd.
751,489
0.04%
-716,799
0.01%
12/31/2017
Morgan Stanley Huaxin Fund Management Co., Ltd.
659,350
0.03%
570,350
0.05%
12/31/2017
| Address |
No. 29 Beijing Road
Harbin Heilongjiang 150025
China
|
|
Employees
|
- |
| Website |
http://www.gloria.cc |
| Updated |
07/08/2019 |
| Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research and development of biological products. It offers cardiovascular, cerebrovascular and skeletal muscular treatment, and antitumor and nutritional drugs. The company products include creatine phosphate sodium injections, clopidogrel bisulfate tablets, cerebroprotein hydrolysate injections, cervus and cucumis polypeptide injections, calcium levofolinate injections, and potassium and magnesium aspartate injections. |
